Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Earum Pharmaceuticals Ltd - 542724 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday, 29Th May, 2023

 Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 ,inter alia, to consider and approve We wish to inform you that the meeting of the Board of Directors of the Company held on Tuesday, 23rd May, 2023 at 4:00 P.M., now is rescheduled on Monday, 29th May, 2023 at 4:00 P.M. at the Registered Office of the Company situated at A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola, Ahmedabad - 380060, to consider and approve the Audited Financial Results of the Company for the Quarter and Year ended on 31st March, 2023 along with Auditor's Report and Declaration. The above intimation is given to you pursuant to Regulation 29 of the SEBI (LODR) Regulations, 2015.
23-05-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 23Rd May, 2023

 We hereby inform you that the meeting of the Board of Directors of the Company is rescheduled and will be held on Monday, 29th May, 2023 at 4:00 P.M. to consider and approve the Audited Financial Results of the Company for the Quarter and Year ended on 31st March, 2023 along with Auditor's Report and Declaration.
23-05-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 23Rd May, 2023

 Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 ,inter alia, to consider and approve We hereby inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, 23rd May, 2023 at 4:00 P.M. at the Registered Office of the Company situated at A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola, Ahmedabad 380060, inter alia, to consider and approve the Audited Financial Results of the Company for the Quarter and Year ended on 31st March, 2023 along with Auditor's Report. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE, the Trading Window has been closed with effect from 1st April, 2023 and shall continue to remain closed till 48 hours after the announcement of the financial results on 23rd May, 2023.
10-05-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 84 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Company has given Newspaper Advertisement on 28th April, 2023 of notice of Rights Issue of Equity Shares.
28-04-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyEarum Pharmaceuticals Ltd 2CIN NO.L24230GJ2012PLC071299 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 8.74 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Madhuri Mistry Designation: Company secretary EmailId: cs@earumpharma.com Name of the Chief Financial Officer: Payal Bhumishth Patel Designation: Chief Financial Officer EmailId: cs@earumpharma.com Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Subject: Submission Of Certificate Under Regulation 40(9) Read With Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2023

 With reference to the captioned subject, kindly find attached herewith Certificate issued under Regulation 40(9) read with Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on 31st March, 2023.
21-04-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 19Th April, 2023

 Pursuant to second proviso to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held today i.e. 19th April, 2023 at the Registered Office of the Company which commenced at 3:00 P.M. and concluded at 3:30 P.M. inter-alia has: 1. Considered and adopted Letter of Offer and Abridged Letter of Offer to be filed with BSE Limited and any other authority, as applicable and will be dispatched to the Eligible Equity Shareholders of the Company as on the Record Date i.e. 10th April, 2023. 2. Decided the schedule of the Rights Issue: Particulars Date Issue opening day and date Tuesday, 2nd May, 2023 Last date for On Market Renunciation of the Rights Entitlements* Friday, 26th May, 2023 Issue closing day and date# Wednesday, 31st May, 2023
19-04-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 With reference to the captioned subject, we hereby submit the confirmation Certificate received from M/s. Bigshare Services Private Limited, Registrar and Share Transfer Agent (RTA) as per Regulation 74(5) of the Securities and Exchange Board India (Depository and Participant) Regulations, 2018 for the Quarter ended on 31st March, 2023.
14-04-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2023.

 With reference to the captioned subject, kindly find attached herewith Certificate issued under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the financial year ended on 31st March, 2023.
14-04-2023
Bigul

Earum Pharmaceuticals Ltd - 542724 - Closure of Trading Window

 Pursuant to Clause 4 of Schedule B of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, this is to inform that the trading window for dealing in Equity Shares of the Company by the Insiders will be closed from Saturday, 1st April, 2023 till 48 hours after the declaration and publication of Audited Financial Results for the Quarter and Year ended on 31st March, 2023
31-03-2023
Next Page
Close

Let's Open Free Demat Account